You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

331 Results
The Radiation Treatment Program ensures timely access to safe, evidence-based, high-quality radiation treatment. To improve patient experience and...
Drug
Other Name(s): Abraxane®
Dec 2024
Drug
Other Name(s): Opdualag™
Feb 2025
Drug
Other Name(s): Jakavi®
Mar 2025
Drug
Other Name(s): Zejula
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Intent: Palliative
Funding:
Exceptional Access Program
    ruxolitinib - For patients with intermediate to high risk symptomatic myelofibrosis, or patients with symptomatic splenomegaly, according to specific criteria
Exceptional Access Program
    ruxolitinib - For the treatment of patients with polycythemia vera according to criteria.
Mar 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    niraparib - For the maintenance treatment of newly diagnosed or recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, according to clinical criteria
Mar 2025
Recognizing the challenge and opportunity of take-home cancer medications, Cancer Care Ontario hosted a policy planning and consultation session in...
Reconnaissant le défi et la possibilité des médicaments contre le cancer à prendre à la maison, Action Cancer Ontario a organisé une séance de...

Pages